Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III randomized, double-blind placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative locally advanced or metastatic breast cancer which progressed on or after aromatase inhibitor treatment

Next Previous
X
Search
Trial Profile

A phase III randomized, double-blind placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative locally advanced or metastatic breast cancer which progressed on or after aromatase inhibitor treatment

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Dec 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Buparlisib (Primary) ; Fulvestrant
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms BELLE-2
  • Sponsors Novartis; Novartis Pharmaceuticals

    • Most Recent Events

    • 05 Dec 2019 This trial has been discontinued in United Kingdom, according to European Clinical Trials Database
    • 19 Jul 2019 This trial has been completed in Netherlands , according to European Clinical Trials Database
    • 10 Jul 2019 As per European Clinical Trials Database record this trial is prematurely ended in Slovakia.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top